CAMBRIDGE, Mass.—(BUSINESS WIRE)—Mar. 17, 2015—OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, is pleased to announce that Michelle Dipp, M.D., Ph.D., was elected to join the World Economic Forum’s Young Global Leaders (YGL). Dr. Dipp’s commitment to the global community – particularly the fertility community – as well as her leadership and the contributions she has made to the healthcare industry throughout her career, led to her selection as one of the world’s most outstanding next-generation leaders.
Dr. Dipp joins other notable YGLs, including: Elon Musk, Co-Founder and Chief Executive Officer of Tesla; Marissa Mayer, Chief Executive Officer of Yahoo; Mark Zuckerberg, Founder and Chief Executive Officer of Facebook; David Rhodes, President of CBS News; Valerie Casey, Chief Product Officer, Global Innovation Center at Samsung; and Toru Hashimoto, Mayor of Osaka City, Japan.
“The YGLs include the world’s most pioneering leaders who have developed in their journey to produce positive, tangible impacts in their countries, industries and societies,” said John Dutton, Director and Head of the Young Global Leaders Community at the World Economic Forum. “The class of 2015, together with the community over the past 10 years, shows how the future of business and public leadership is becoming more gender-equal, more geographically diverse, more varied in its expertise and is challenging established ways to get things done.”
“This is a great opportunity to join other global leaders who have already had such a positive effect on and remain committed to improving the lives of others,” said Dr. Dipp. “I look forward to what we can accomplish together to address the challenges of and expand the opportunities for building a greater global community.”
To learn more about the YGL community, visit http://www.weforum.org/community/forum-young-global-leaders.
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.
This press release includes forward-looking statements about the Company’s business and development plans for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
Cara Mayfield, Director, Corporate Communications, 617-714-9638